Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1

Interventions

Cisplatin 32Radiotherapy, Intensity-Modulated 17Radiotherapy 17Carboplatin 14Radiation 11Magnetic Resonance Spectroscopy 10Cetuximab 8Specimen Handling 7Platinum 7Paclitaxel 71,2-diaminocyclohexaneplatinum II citrate 7Docetaxel 6Chemoradiotherapy 6Surgical Procedures, Operative 5pembrolizumab 4Nivolumab 4Celecoxib 4cemiplimab 3Taxes 3Surveys and Questionnaires 3Fluorouracil 3Drug Therapy 3toripalimab 2durvalumab 2aldesleukin 2X-Rays 2Standard of Care 2Restraint, Physical 2Observation 2Neck Dissection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oropharyngeal Neoplasms × utomilumab × Clear all
NCT03258008 2022-12-16

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡